II期临床-话题@MedSci

#II期临床#

478篇内容 | 2564人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524887, encodeId=e1b9152488e1f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, objectType=article, longId=202718, objectId=5865202e1851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5865202e1851, replyNumber=0, likeNumber=74, createdTime=2020-11-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5865202e1851, moduleTitle=Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5865202e1851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524886, encodeId=181815248867d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, objectType=article, longId=202653, objectId=fcf72026535d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcf72026535d, replyNumber=0, likeNumber=44, createdTime=2020-10-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcf72026535d, moduleTitle=NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcf72026535d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524885, encodeId=55ed1524885e0, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, objectType=article, longId=202651, objectId=9ce020265159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ce020265159, replyNumber=0, likeNumber=74, createdTime=2020-10-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ce020265159, moduleTitle=补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ce020265159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524884, encodeId=13e4152488417, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=77, createdTime=2020-10-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524883, encodeId=a10a152488319, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据, objectType=article, longId=202473, objectId=2a172024e33a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a172024e33a, replyNumber=0, likeNumber=103, createdTime=2020-10-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a172024e33a, moduleTitle=GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a172024e33a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524882, encodeId=9c671524882d8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症, objectType=article, longId=202091, objectId=a75320209101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a75320209101, replyNumber=0, likeNumber=82, createdTime=2020-10-15, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a75320209101, moduleTitle=II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a75320209101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524881, encodeId=6230152488139, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, objectType=article, longId=201999, objectId=9dcd20199981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9dcd20199981, replyNumber=0, likeNumber=0, createdTime=2020-10-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9dcd20199981, moduleTitle=瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9dcd20199981)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524880, encodeId=640a1524880a3, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=X-连锁色素性视网膜炎（XLRP）基因疗法I/II期临床：显著改善视网膜敏感性, objectType=article, longId=201996, objectId=1f8e201996f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f8e201996f6, replyNumber=0, likeNumber=61, createdTime=2020-10-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f8e201996f6, moduleTitle=X-连锁色素性视网膜炎（XLRP）基因疗法I/II期临床：显著改善视网膜敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f8e201996f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524879, encodeId=aff115248e951, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, objectType=article, longId=201995, objectId=a7e920199565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e920199565, replyNumber=0, likeNumber=70, createdTime=2020-10-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e920199565, moduleTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e920199565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524878, encodeId=da5015248e8ee, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=单抗III期临床试验失败案例及原因分析, objectType=article, longId=201985, objectId=5e8f20198506, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e8f20198506, replyNumber=0, likeNumber=92, createdTime=2020-10-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e8f20198506, moduleTitle=单抗III期临床试验失败案例及原因分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e8f20198506)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524877, encodeId=05a115248e73b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=p38α抑制剂Neflamapimod治疗路易体痴呆症的II期临床成功，患者认知显着提高, objectType=article, longId=201946, objectId=8c3820194642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3820194642, replyNumber=0, likeNumber=58, createdTime=2020-10-12, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3820194642, moduleTitle=p38α抑制剂Neflamapimod治疗路易体痴呆症的II期临床成功，患者认知显着提高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3820194642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524876, encodeId=788815248e67d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床, objectType=article, longId=201817, objectId=ab3520181ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab3520181ee0, replyNumber=0, likeNumber=70, createdTime=2020-10-09, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab3520181ee0, moduleTitle=GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab3520181ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524875, encodeId=20c015248e50f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , objectType=article, longId=201778, objectId=df60201e785f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df60201e785f, replyNumber=0, likeNumber=72, createdTime=2020-10-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df60201e785f, moduleTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df60201e785f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524874, encodeId=fc8a15248e4e9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=108, createdTime=2020-10-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524873, encodeId=ed7415248e364, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, objectType=article, longId=201506, objectId=3857201506d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3857201506d7, replyNumber=0, likeNumber=84, createdTime=2020-10-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3857201506d7, moduleTitle=Xevinapant治疗头颈癌：步入大型III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3857201506d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524872, encodeId=0a3415248e28c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, objectType=article, longId=201486, objectId=14fc201486bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fc201486bd, replyNumber=0, likeNumber=111, createdTime=2020-10-03, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fc201486bd, moduleTitle=强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fc201486bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524871, encodeId=97b915248e190, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, objectType=article, longId=201382, objectId=2172201382b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2172201382b6, replyNumber=0, likeNumber=121, createdTime=2020-10-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2172201382b6, moduleTitle=君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2172201382b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524870, encodeId=59d215248e071, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, objectType=article, longId=201330, objectId=7e8920133089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e8920133089, replyNumber=0, likeNumber=94, createdTime=2020-09-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e8920133089, moduleTitle=雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e8920133089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524869, encodeId=a31715248690c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, objectType=article, longId=201324, objectId=3539201324d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3539201324d6, replyNumber=0, likeNumber=67, createdTime=2020-09-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3539201324d6, moduleTitle=Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3539201324d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524868, encodeId=0eeb15248689c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, objectType=article, longId=201182, objectId=099320118291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=099320118291, replyNumber=0, likeNumber=47, createdTime=2020-09-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=099320118291, moduleTitle=Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=099320118291)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lenzilumab预防COVID-19“细胞因子风暴”：已开展III期临床试验

2020-11-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NMPA批准针对痴呆症的18F-APN-1607 Tau PET成像示踪剂的III期临床试验

2020-10-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

补体C5a受体选择性抑制剂Avacopan治疗化脓性汗腺炎（HS）：II期临床试验取得阳性结果

2020-10-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2020-10-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

GC4419治疗晚期胰腺癌的I/II期临床试验：已取得阳性数据

2020-10-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

II期临床：白介素23单抗Mirikizumab持续改善克罗恩病患者症状并减少肠道炎症

2020-10-15

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

瑞德昔韦联合血浆来源中和抗体：开展III期临床评价抗新冠病毒COVID-19的有效性

2020-10-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

X-连锁色素性视网膜炎（XLRP）基因疗法I/II期临床：显著改善视网膜敏感性

2020-10-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败

2020-10-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

单抗III期临床试验失败案例及原因分析

2020-10-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

p38α抑制剂Neflamapimod治疗路易体痴呆症的II期临床成功，患者认知显着提高

2020-10-12

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

GSK和Vir Biotechnology将抗SARS-CoV-2单克隆抗体推荐到III期临床

2020-10-09

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？

2020-10-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2020-10-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Xevinapant治疗头颈癌：步入大型III期临床试验

2020-10-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

强生新冠疫苗进入III期临床试验，大选前疫苗出炉有望吗？

2020-10-03

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

君实生物特瑞普利单抗一线治疗鼻咽癌III期临床研究PFS预估显著

2020-10-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

雾化Ensifentrine治疗慢性阻塞性肺疾病（COPD）：即将开展III期临床试验

2020-09-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Novavax已在英国开始COVID-19候选疫苗NVX-CoV2373的III期临床试验

2020-09-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Br J Cancer：III期临床试验：选择性淋巴结照射和或厄洛替尼联合放化疗改善局部晚期食道鳞状细胞癌患者长期生存率

2020-09-26

科室
- - 订阅+
  - 更多科室
工具
服务